<?xml version='1.0' encoding='utf-8'?>
<document id="17368862"><sentence text="Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats."><entity charOffset="23-35" id="DDI-PubMed.17368862.s1.e0" text="tandospirone" /><entity charOffset="50-59" id="DDI-PubMed.17368862.s1.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.17368862.s1.e0" e2="DDI-PubMed.17368862.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17368862.s1.e0" e2="DDI-PubMed.17368862.s1.e1" /></sentence><sentence text="The purpose of this study was to investigate the effects of co-administration of tandospirone (a 5-HT(1A) receptor agonist) and individual selective serotonin reuptake inhibitors (SSRIs) on the contextual conditioned fear stress, using an anxiety model in rats"><entity charOffset="81-93" id="DDI-PubMed.17368862.s2.e0" text="tandospirone" /><entity charOffset="149-158" id="DDI-PubMed.17368862.s2.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.17368862.s2.e0" e2="DDI-PubMed.17368862.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17368862.s2.e0" e2="DDI-PubMed.17368862.s2.e1" /></sentence><sentence text=" One day after fear conditioning, tandospirone (0"><entity charOffset="34-46" id="DDI-PubMed.17368862.s3.e0" text="tandospirone" /></sentence><sentence text="3-3 mg/kg, s" /><sentence text="c" /><sentence text="), paroxetine (5-20 mg/kg, i"><entity charOffset="3-13" id="DDI-PubMed.17368862.s6.e0" text="paroxetine" /></sentence><sentence text="p" /><sentence text="), fluvoxamine (30-60 mg/kg, i"><entity charOffset="3-14" id="DDI-PubMed.17368862.s8.e0" text="fluvoxamine" /></sentence><sentence text="p" /><sentence text=") and citalopram (3-30 mg/kg, i"><entity charOffset="6-16" id="DDI-PubMed.17368862.s10.e0" text="citalopram" /></sentence><sentence text="p" /><sentence text=") significantly inhibited the conditioned freezing in a dose-dependent manner, whereas, 14 days after fear conditioning, the anxiolytic effects of these drugs were weakened" /><sentence text=" Fourteen days after fear conditioning, co-administration of tandospirone (0"><entity charOffset="61-73" id="DDI-PubMed.17368862.s13.e0" text="tandospirone" /></sentence><sentence text="3 mg/kg, s" /><sentence text="c" /><sentence text=") with each SSRI [paroxetine (5 mg/kg, i"><entity charOffset="18-28" id="DDI-PubMed.17368862.s16.e0" text="paroxetine" /></sentence><sentence text="p" /><sentence text="), fluvoxamine (30 mg/kg, i"><entity charOffset="3-14" id="DDI-PubMed.17368862.s18.e0" text="fluvoxamine" /></sentence><sentence text="p" /><sentence text=") and citalopram (10 mg/kg, i"><entity charOffset="6-16" id="DDI-PubMed.17368862.s20.e0" text="citalopram" /></sentence><sentence text="p" /><sentence text=")], given at subeffective doses, markedly inhibited the conditioned freezing without affecting the locomotor activities and CYP3A4-related pharmacokinetic drug-drug interaction" /><sentence text=" These results elucidate the pharmacodynamic synergistic effects of tandospirone and SSRIs"><entity charOffset="68-80" id="DDI-PubMed.17368862.s23.e0" text="tandospirone" /></sentence><sentence text=" Therefore, this augmentation therapy (SSRI+5-HT(1A) receptor agonist) may prove useful for some anxiety disorders" /><sentence text="" /></document>